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Background and Aims: Despite the recent spread of hepatitis C virus genotype 4 (HCV-4) into European countries, very 
little is known about the influence of ethnicity on treatment outcomes in patients with HCV-4. The aim of this study was 
to compare the virologic response (VR) rates of: rapid virologic response (RVR), early virologic response (EVR), VR at 24 
weeks of treatment, at end of treatment (EoT), and sustained virologic response (SVR) of European and Egyptian HCV-4 
patients. 
Methods: Sixty (30 Europeans – Group A; and 30 Egyptians – Group B) chronic HCV-4 subtype A adult patients with elevated 
baseline viral load (>800 000 IU/m L) were treated for a fixed period of 48 weeks with pegylated interferon α2a (PEG-IFN-
α2a) and ribavirin. During the study, HCV RNA levels were measured at weeks 4,12,24,48 and 72.
Results: Baseline characteristics, including liver histology, were similar in the two groups. RVR, EVR and HCV RNA at 
week 24 in Groups A and B were (RVR 26.7% vs. 30.0%) (EVR 23.3% vs. 16.7%) (in week 24 13.3% vs. 16.7%). Overall 
SVR rates were 36.7% (11/30) for Group A and 26.7% (8/30) for Group B (P = 0.59). For group B, RVR was the weakest 
indicator for SVR as compared with RVR of group A, where RVR was the best SVR indicator.
Conclusions: The overall response to treatment was similar, but ethnic origin or previous history and treatment of schisto-
somiasis may influence intermediate response rates of chronic HCV-4a infected patients with elevated baseline HCV RNA. 
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Introduction
H
epatitis C virus (HCV) infection is a major 
health  problem  with  an  estimated  175 
million  infected  people  worldwide  (1).  At  least  6 
major  HCV  genotypes  have  been  identified,  and 
each one differs from the others by 30%-35% of its 
nucleotide site sequence (1, 2).
HCV genotype 4 (HCV-4) is common in the 
Middle East and in Africa, where it is responsible for 
more than 80% of HCV infections (3).
In Egypt, where hepatitis C is highly endemic, 
HCV-4 is the predominant subtype (3, 4). Recently, Hepatitis Monthly, Summer 2010; 10(3): 193-198
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HCV-4 has become increasingly prevalent in some 
southern European countries on the Mediterranean 
Sea, with prevalence rates ranging between 7.4% and 
13.2% (5-8). 
The HCV-4 incidence in Greece has been reported 
to be 13.2% with a temporal pattern of moderate 
increase. Subtype 4a is the most common (78%) and 
the phylogenetic comparison of Greek 4a isolates has 
not revealed any discrimination from the HCV-4a 
isolates reported worldwide (7).
  Fibrosis  progression  in  HCV-4  infection  has 
been assessed in longitudinal studies (9-11). One of 
these comparing French, Egyptian and Sub-Saharan 
African HCV patients revealed significantly higher 
grading  and  staging  scores  in  Egyptian  patients 
infected with HCV-4a (11). It has been hypothesized 
that  these  higher  scores  might  be  attributed  to 
the  concomitant  schistosomiasis  in  the  patient 
subpopulations reported above.
Because conventional interferon alpha (IFN-α) 
monotherapy has resulted in disappointing virologic 
responses, HCV-4 has been considered difficult to 
treat (12-14). Recent reports show that the combination 
of pegylated interferon α (PEG-IFN-α) with ribavirin 
markedly improves therapeutic outcomes, resulting 
in sustained virologic response (SVR) rates ranging 
between 44% and 69% (15-18).
Despite the data reported above, the management 
strategies for patients infected with HCV-4 are not 
yet well established. The limited distribution of this 
genotype  in  Western  countries  and  subsequently 
the small percentage of HCV-4 patients in major 
multicenter  HCV  therapeutic  trials  may  in  part 
explain this phenomenon.
On the other hand, very little is known about the 
influence of ethnic origin on the treatment outcome 
in this patient population. 
Materials and Methods
From 2003 to 2007, 60 treatment-naïve chronic 
HCV-4a  adult  patients,  in  total,  were  referred  to 
the  Gastroenterology-Hepatology  and  Internal 
Medicine-Hepatology departments of three tertiary 
care hospitals in Athens, Greece, for the management 
of hepatitis C. 
 Patients were stratified into two groups based on 
their ethnicity. Group A consisted of 30 consecutively 
eligible consenting European patients (24 males, 6 
females),  and  group  B  included  30  consecutively 
eligible consenting Egyptian patients (27 males, 3 
females). All patients were treated with PEG-IFN-
α2a (Pegasys; Roche, Basel, Switzerland) 180 μg/wk 
administered  subcutaneously  in  combination  with 
oral ribavirin (Copegus 200 mg tablets; Roche) in a 
dose of 1000 or 1200 mg/day depending on baseline 
body weight ≤ or > 85 Kg, respectively, divided into 
two doses, for a period of 48 weeks.
End Points
The primary end point of the present open-label 
non-interventional study was to compare the SVR 
rates  between  two  ethnic  groups  (Europeans  and 
Egyptians)  of  chronic  HCV-4a  infected  patients 
with  elevated  HCV  RNA  pretreatment  levels. 
Both groups were treated with the combination of 
PEG-IFN with ribavirin for a period of 48 weeks. 
Secondary  end  points  were  to  determine  the 
evaluation of rapid virologic response (RVR), early 
virologic response (EVR), and 24 week HCV RNA 
negativity as prognostic factors of SVR in the two 
studied populations. Additionally, evaluation of the 
safety of the treatment reported above with respect to 
depression and abnormal laboratory values was also 
performed. SVR was defined as having undetectable 
levels of HCV RNA 24 weeks after the EoT (week 
72).
To the best of our knowledge a direct comparative 
study  between  chronic  HCV-4a  Europeans  and 
Egyptians with high pretreatment HCV RNA levels, 
taking into account virologic response rates, has not 
been reported in the literature.
Patients were eligible for the study only if they were 
infected with genotype 4, subtype A, hepatitis C virus 
and they presented with HCV levels (Versant HCV 
RNA 3,0, Bayer Diagnostics LLC , Tarrytown, NY, 
USA ) > 800000 IU/ml during the previous months 
before enrollment in the study. Other inclusion criteria 
were  testing  anti-HCV  positive,  and  liver  biopsy 
performed within 6 months before treatment.
Exclusion criteria for both groups were: ethnic 
origin  other  than  European  or  Egyptian,  severe 
or  untreated  psychiatric  illness,  decompensated 
liver  cirrhosis,  coinfection  with  hepatitis  B  or 
human  immunodeficiency  virus  or  the  presence 
of  schistosoma  mansoni,  chronic  alcohol  abuse, 
pregnancy  or  lactation,  severe,  difficult-to-treat 
cardiac  or  neurologic  disease,  insulin-treated 
diabetes  mellitus  (due  to  the  negative  influence 
of  insulin  resistance  on  antiviral  therapy), 
hepatocellular  carcinoma  (HCC)  evaluated  by 
ultrasound  and  alpha  fetoprotein  level,  prior 
history of any other malignancy or active malignant 
disease, autoimmune disorders, previous treatment 
with IFN-α, hemoglobin level < 120g/L in women 
and < 130 g/L in men, a neutrophil count <1500/ 
mm3 and a platelet count < 75000/mm3 .
The study was approved by the ethics committees 
of all of the hospitals involved. All patients signed Hepatitis Monthly, Summer 2010; 10(3): 193-198
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Fig. 1 illustrates the overall HCV RNA negativity 
rates in both groups during the weeks 4, 12, 24, 48 
and 72. 
Safety,  use  of  antidepressants  and  abnormal 
laboratory values
There  were  no  life-threatening  adverse  events 
during  the  study  and  no  patients  withdrew  from 
the treatment because of a severe adverse event or 
laboratory abnormality.
Dose  reduction  of  ribavirin  was  made  in  5 
(16.7%) patients from group A, and 2 (6.7%) from 
group B. Dose reduction of PEG-IFN-α2a was made 
in 4 (13.3%) patients from group A, and 3 (10%) 
from group B. Antidepressants (mitrazapine) were 
prescribed to 4 (13.3%) patients from group A.
No statistically significant percentage of abnormal 
hemoglobin,  white  blood  cell,  neutrophil,  and 
platelet count values were noted in the two studied 
groups during the treatment period (data not shown). 
Patients from group B presented significantly higher 
percentages of abnormal ALT and γGT values at week 
24 (50.0% vs. 20.0% P = 0.03; 40.0% vs. 13.3% P = 
0.04) (Data not shown). 
Discussion
Very  little  is  known  about  the  influence  of 
ethnic origin on the treatment outcomes in patients 
chronically infected with HCV-4 (4). Results from 
clinical trials conducted in the Middle East and Egypt, 
using PEG-IFN plus ribavirin, indicated SVR rates 
ranging between 65% and 69% (15, 16, 18-20). On the 
other hand, there are very few similar studies conducted 
in Europe, and none in the U.S.A. (21-24). The vast 
majority of these included very small numbers of non-
Sub-Saharan African and non-Egyptian patients, while 
others  included  individuals  coinfected  with 
HIV.  SVR  rates  ranging  between  16.7%  and 
79% have been reported from these studies.
A retrospective analysis of SVR rates among 
205 naïve French and Egyptian HCV-4 patients 
revealed a better overall response in Egyptians 
than in Europeans (54.9% vs. 40.3%) treated 
with PEG-IFN and ribavirin (11). 
 In our study, the RVR and overall SVR rates 
(week 72) were similar in the two groups, but 
the manner in which overall SVR was achieved 
was different. In the European group, RVR was 
the best indicator of SVR (63%), with the lowest 
SVR rate (50%) in those who attained HCV 
RNA negativity at week 24. For the Egyptian 
group, RVR was the weakest indicator of SVR 
(11%), and HCV RNA negativity at week 24 
presented the best SVR (100%) (Table 2). 
The failure of the subjects at week 4 to achieve 
a  similar  SVR  in  the  Egyptian  group,  after 
having had a similar RVR rate to the European 
group,  along  with  the  knowledge  that  the  overall 
SVR was similar, suggests the possibility of a delay in 
the maintenance of treatment effect in the Egyptian 
population.  The  fact  that  both  groups  eventually 
do achieve similar overall SVR, keeping in mind the 
increased EVR and 100% SVR of the week 24 Egyptian 
group, strongly suggests that Egyptian patients respond 
to  the  PEG-IFN-α2a  and  ribavirin  similarly  to  the 
European  group,  after  the  delay  period  passes. The 
possibility of a treatment delay, a type of bias present 
in patients with previous schistosomiasis infection due 
to the long-lasting liver fibrosis which it may cause, has 
been suggested by previous research (11).
Whether the delay in treatment response is related 
to the high incidence of previous schistosomiasis or 
to physiological differences in the Egyptian group in 
this study is not clear. 
Although  our  SVR  results  are  lower  than  the 
ones reported by Roulot et al. (36.7% vs. 40.3% for 
the European patients and 26.7% vs. 54.9% for the 
Egyptians), in a quite similar total number of HCV-
4a-infected  individuals,  the  statistical  difference 
of SVR rates between the two populations is not 
significant in either of the studies. In comparing our 
results for the European group with those of a recent 
Austrian  study,  with  a  completely  different  study 
design, a lower EVR rate was observed (23.3% vs. 
42.4%), but information concerning the ethnicity of 
patients and also the viral subtype and the baseline 
viral  load  of  those  who  achieved  EVR  was  not 
provided (25). On the other hand, the small number 
RNA (-) week 4 RNA (-) week 12 RNA (-) week 24 RNA (-) week 48 RNA (-) week 72
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of patients (9) with a viral load >400000 IU/ ml who 
achieved SVR makes any direct comparison with our 
results difficult.
Analysis of virologic response rates in the European 
group at weeks 4, 12 and 24 revealed that RVR was 
the most likely predictor of SVR (63% 5/8), while for 
Egyptian patients, HCV RNA negativity at week 24 
was the best indicator of SVR (100% 5/5) (Table 2).
EVR can be considered a moderate prognostic 
factor for SVR for our European population (57%, 
4/7), with a lower percentage for Egyptians (40%, 
2/5). RVR rates among patients with SVR from both 
treated groups were as follows: 45.4%-5/11 for group 
A and 11.1%-1/9 for group B (Table 2). Although 
is  difficult  to  provide  a  complete  explanation  for 
this difference, the small number of patients in the 
study and the advanced stage in liver histology of 
the Egyptian population (P < 0.001), due probably 
to the younger age of contamination, may provide 
a  partial  explanation.  The  presence  of  insulin 
resistance, which was not included in our study, may 
also affect the differences in viral kinetics between 
the two studied groups (26, 27). The expression of the 
MxA gene at the beginning of treatment may also be 
an important prognostic factor for SVR in chronic 
HCV-4-infected patients (28, 29).
These results are different from the ones reported by 
Ferenci et al. for HCV-4- infected patients with baseline 
HCV RNA >800000 IU/ml, but the number of patients 
on which the conclusion is based, in the study reported 
above, is quite small (6 individuals) (25).
Studies of Egyptian and Saudi Arabian HCV-4- 
infected  individuals  with  elevated  baseline  HCV 
RNA have reported higher SVR rates (65.0% and 
42.9%  respectively)  than  those  achieved  in  the 
present study (15, 17). Although the genetic distance 
and heterogenecity between quasispecies can play a 
critical role as a predictor of IFN-based response, 
the  unclear  percentage  of  HCV-4a  individuals 
and  the  unknown  number  of  patients  with  high 
pretreatment viral load who achieved SVR make any 
direct comparison with our results difficult (26).
In  a  recent  study,  Kamal  et  al.,  have  examined 
the significance of RVR and EVR as predictors for 
SVR in a group of HCV-4-infected Egyptians for a 
treatment duration of 48 weeks, and reported an RVR 
rate of 14% and an EVR rate of 26% for those who 
achieved SVR (19). Although the limitations reported 
above still remain, our results concerning the Egyptian 
population are in agreement with these findings.
Conclusions
The  direct  comparison  between  European  and 
Egyptian HCV-4a-infected individuals with elevated 
baseline viral load treated with PEG-IFN-α2a and 
ribavirin for 48 weeks showed a higher SVR rate for 
the European population. RVR was a good indicator 
of  SVR  in  the  European  group,  while  for  the 
Egyptians 24 week HCV RNA negativity provided 
the best prognostic factor for SVR. Overall SVR was 
similar  in  both  groups. The  proposed  therapeutic 
approach was well tolerated by all patients. Further 
studies are needed to validate our results and also 
to  evaluate  possible  application  to  other  HCV-4 
groups. The individualization of HCV treatment for 
Egyptian patients, and the possibility of a change in 
the therapeutic algorithm for all genotype 4 patients 
should also receive further evaluation.
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